Stocktwits on MSN
BIIB, DNLI stocks edge lower after hours: Parkinson’s drug misses key goals in trial
Despite the miss, the companies said the medicine was generally well tolerated with an acceptable safety profile and ...
Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics ...
Biogen has rallied the broader market over the past year, and analysts remain moderately optimistic about the stock’s ...
On April 20, 2026, Reuters reported that Biogen Inc. (NASDAQ:BIIB) had agreed to pay up to $850 million for the exclusive ...
Members of Congress have traded $BIIB stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales. Here’s a breakdown of recent ...
Stocktwits on MSN
Biogen’s latest Alzheimer’s bet didn’t fully succeed – but still sent BIIB stock soaring
Biogen said the overall biomarker and efficacy data were strong enough to advance the drug into registrational development, ...
Prominent biotech Biogen (NASDAQ: BIIB) loomed large on the stock market on Wednesday. It published its latest set of quarterly earnings, and investors greeted the estimates-beating numbers by piling ...
Biogen Inc. (NASDAQ:BIIB) ranks among the most undervalued NASDAQ stocks to buy now. On September 18, Biogen Inc. (NASDAQ:BIIB) announced that it had finalized a deal to acquire Alcyone Therapeutics ...
Members of Congress have traded $BIIB stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales. Here’s a breakdown of recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results